ERBB3 and neoplasm: While the mechanism of action of the miRNAs is different from the anti-HER3 blocking Abs, this novel approach aims to reduce the protein levels of HER3 rather than just inhibit its signaling, which may eliminate the chance for tumor cells to develop resistance after initial response.